These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2765404)

  • 1. Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukaemic blast progenitors in acute myelogenous leukaemia.
    Maruyama Y; Murohashi I; Nara N; Aoki N
    Br J Haematol; 1989 Jul; 72(3):357-62. PubMed ID: 2765404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
    Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
    Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells.
    Hegewisch-Becker S; Faltz C; Hossfeld DK
    Eur J Haematol; 1996; 56(1-2):12-22. PubMed ID: 8599988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia.
    Ross DD; Joneckis CC; Schiffer CA
    Blood; 1986 Jul; 68(1):83-8. PubMed ID: 3719105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
    Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daunorubicin (DNR) accumulation in fresh leukemic cells: correlation with clinical and biological features.
    Boiron JM; Belloc F; Montastruc M; Cony-Makhoul P; Marit G; Puntous M; Dumain P; Lacombe F; Dubosc-Marchenay N; Fabères C
    Leuk Lymphoma; 1994 Apr; 13(3-4):291-6. PubMed ID: 8049651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
    Kokenberg E; Sonneveld P; Delwel R; Sizoo W; Hagenbeek A; Löwenberg B
    Leukemia; 1988 Aug; 2(8):511-7. PubMed ID: 3166077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
    Campos L; Guyotat D; Jaffar C; Solary E; Archimbaud E; Treille D
    Eur J Haematol; 1992 May; 48(5):254-8. PubMed ID: 1353726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation.
    Xu D; Knaust E; Pisa P; Palucka K; Lundeberg J; Areström I; Peterson C; Gruber A
    Br J Haematol; 1996 Mar; 92(4):847-54. PubMed ID: 8616077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
    Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
    Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
    Berman E; McBride M
    Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin.
    Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
    Haematologica; 2000 Feb; 85(2):124-32. PubMed ID: 10681718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
    Boiron JM; Belloc F; Montastruc M; Cony-Makhoul P; Dumain P; Marit G; Mahon FX; Puntous M; Lopez F; Lacombe F
    Leuk Res; 1994 May; 18(5):313-8. PubMed ID: 8182921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line.
    Wang YH; Motoji T; Motomura S; Shiozaki H; Tsuruo T; Mizoguchi H
    Eur J Haematol; 1997 Mar; 58(3):186-94. PubMed ID: 9150713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells.
    Friche E; Skovsgaard T; Nissen NI
    Cancer Chemother Pharmacol; 1987; 19(1):35-9. PubMed ID: 3815723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.
    Ross DD; Wooten PJ; Tong Y; Cornblatt B; Levy C; Sridhara R; Lee EJ; Schiffer CA
    Blood; 1994 Mar; 83(5):1337-47. PubMed ID: 8118035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
    Kokenberg E; Sonneveld P; Sizoo W; Hagenbeek A; Löwenberg B
    J Clin Oncol; 1988 May; 6(5):802-12. PubMed ID: 3163363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML).
    Marie JP; Helou C; Thevenin D; Delmer A; Zittoun R
    Exp Hematol; 1992 Jun; 20(5):565-8. PubMed ID: 1350249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors.
    Curtis JE; Minden MD; Minkin S; McCulloch EA
    Leukemia; 1995 Mar; 9(3):396-404. PubMed ID: 7533865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric assessment of multidrug resistance (MDR) phenotype in acute myeloid leukaemia.
    Hart SM; Ganeshaguru K; Lyttelton MP; Prentice HG; Hoffbrand AV; Mehta AB
    Leuk Lymphoma; 1993 Oct; 11(3-4):239-48. PubMed ID: 7903178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.